Metabolic risk during antipsychotic treatment

Clinical Therapeutics

Volumn 26, Issue 12, 2004, Pages 1936-1946

  Newcomer, John W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse effects; Dyslipidemia; Hyperglycemia; Schizophrenia; Type 2 diabetes mellitus (T2DM)

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; GLUCOSE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT MONITORING; POLYDIPSIA; POLYURIA; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 14844344472     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2004.12.003     Document Type: Article

References (84)

1. Casey DE, Haupt DW, and Newcomer JW Antipsychotic-induced weight gain and metabolic abnormalities: Implications for increased mortality in patients with schizophrenia J Clin Psychiatry 65 Suppl 7 2004 4 18
2. Gray DS Diagnosis and prevalence of obesity Med Clin North Am 73 1989 1 13
3. Calle EE, Thun MJ, and Petrelli JM Body-mass index and mortality in a prospective cohort of U.S. adults N Engl J Med 341 1999 1097 1105
4. Banerji MA, Lebowitz J, and Chaiken RL Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects Am J Physiol 273 1997 E425 E432
5. discussion 75-82 Reaven G Syndrome X: 10 Years after Drugs 58 1999 S19 S20
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
7. Lorenzo C, Okoloise M, Williams K San Antonio Heart Study The metabolic syndrome as predictor of type 2 diabetes: The San Antonio Heart Study Diabetes Care 26 2003 3153 3159
8. Sattar N, Gaw A, and Scherbakova O Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study Circulation 108 2003 414 419
9. Haffner SM, Lehto S, and Ronnemaa T Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 1998 229 234
10. Garg A, and Grundy SM Management of dyslipidemia in NIDDM Diabetes Care 13 1990 153 169
11. Wilson PW, Kannel WB, and Anderson KM Lipids, glucose intolerance and vascular disease: The Framingham Study Monogr Atheroscler 13 1985 1 11
12. Harris MI Health care and health status and outcomes for patients with type 2 diabetes Diabetes Care 23 2000 754 758
13. [published correction appears in Diabetes Care. 2003;26:972] American Diabetes Association Standards of medical care for patients with diabetes mellitus Diabetes Care 26 Suppl 1 2003 S33 S50
14. Koller E, Schneider B, Bennett K, and Dubitsky G Clozapine-associated diabetes Am J Med 111 2001 716 723
15. [in German] Von Hayek D, Huttl D, and Reiss J Hyperglycemia and ketoacidosis associated with olanzapine Nervenarzt 70 1999 836 837
16. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity Consensus development conference on antipsychotic drugs and obesity and diabetes Diabetes Care 27 2004 596 601
17. Pi-Sunyer FX Medical hazards of obesity Ann Intern Med 119 1993 655 660
18. author reply 2089-2090 Boehm G, Racoosin JA, Laughren TP, and Katz R Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes: Response to consensus statement Diabetes Care 27 2004 2088 2089
19. Tabata H, Kikuoka M, and Kikuoka H Characteristics of diabetes mellitus in schizophrenic patients J Med Assoc Thai 70 Suppl 2 1987 90 93
20. Mukherjee S, Decina P, and Bocola V Diabetes mellitus in schizophrenic patients Compr Psychiatry 37 1996 68 73
21. Brown S Excess mortality of schizophrenia. A metaanalysis Br J Psychiatry 171 1997 502 508
22. Dixon L, Weiden P, and Delahanty J Prevalence and correlates of diabetes in national schizophrenia samples Schizophr Bull 26 2000 903 912
23. Okamura F, Tashiro A, and Utumi A Insulin resistance in patients with depression and its changes during the clinical course of depression: Minimal model analysis Metabolism 49 2000 1255 1260
24. Chiba M, Suzuki S, and Hinokio Y Tyrosine hydroxylase gene microsatellite polymorphism associated with insulin resistance in depressive disorder Metabolism 49 2000 1145 1149
25. Mokdad AH, Bowman BA, and Ford ES The continuing epidemics of obesity and diabetes in the United States JAMA 286 2001 1195 1200
26. Haupt DW, and Newcomer JW Abnormalities in glucose regulation associated with mental illness and treatment J Psychosom Res 53 2002 925 933
27. Regenold WT, Thapar RK, and Marano C Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use J Affect Disord 70 2002 19 26
28. Ryan MC, Collins P, and Thakore JH Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia Am J Psychiatry 160 2003 284 289
29. Newcomer JW. Atypical antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs. In press.
30. Allison DB, Mentore JL, and Heo M Antipsychotic-induced weight gain: A comprehensive research synthesis Am J Psychiatry 156 1999 1686 1696
31. Leucht S, Wagenpfeil S, Hamann J, and Kissling W Amisulpride is an "atypical" antipsychotic associated with low weight gain Psychopharmacology (Berl) 173 2004 112 115
32. Marder SR, McQuade RD, and Stock E Aripiprazole in the treatment of schizophrenia: Safety and tolerability in short-term, placebo-controlled trials Schizophr Res 61 2003 123 136
33. Pigott TA, Carson WH, Saha AR Aripiprazole Study Group Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: A placebo-controlled 26-week study J Clin Psychiatry 64 2003 1048 1056
34. McQuade RD, Jody D, and Kujawa M Long-term weight effects of aripiprazole versus olanzapine Poster presented at: 156th Annual Meeting of the American Psychiatric Association San Francisco, Calif. May 17-22, 2003
35. Kasper S, Lerman MN, and McQuade RD Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia Int J Neuropsychopharmacol 6 2003 325 327
36. Available at: Abilify [package insert] pl?sql=select% 20PPI%20from%20TB_PRODUCT_PPI%20where %20_SEQ=101&key=PPI. Accessed September 29, 2004
37. Daniel DG, Zimbroff DL, Potkin SG Ziprasidone Study Group Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial Neuropsychopharmacology 20 1999 491 505
38. Hirsch SR, Kissling W, and Bauml J A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia J Clin Psychiatry 63 2002 516 523
39. Available at: Geodon [package insert] Accessed September 29, 2004
40. Jones AM, Rak IW, and Raniwalla J Weight changes in patients treated with quetiapine Poster presented at: 153rd Annual Meeting of the American Psychiatric Association Chicago, Ill. May 13-18, 2000
41. Available at: Seroquel [package insert] Accessed September 29, 2004
42. [published correction appears in N Engl J Med. 2002;346:1424] Csernansky JG, Mahmoud R, Brenner R Risperidone-USA-79 Study Group A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia N Engl J Med 346 2002 16 22
43. Available at: Risperdal [package insert] Accessed September 29, 2004
44. Nemeroff CB Dosing the antipsychotic medication olanzapine J Clin Psychiatry 58 1997 S45 S49
45. Kinon BJ The routine use of atypical antipsychotic agents: Maintenance treatment J Clin Psychiatry 59 1998 S18 S22
46. Available at: Zyprexa [package insert] Accessed September 29, 2004
47. Mortimer A, Martin S, Loo H, Peuskens J SOLIANOL Study Group A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia Int Clin Psychopharmacol 19 2004 63 69
48. Kasanin J The blood sugar curve in mental disease Arch Neurol Psychiatry 16 1926 414 419
49. discussion 40-41 Haupt DW, and Newcomer JW Hyperglycemia and antipsychotic medications J Clin Psychiatry 62 2001 15 26
50. Newcomer JW, Haupt DW, and Fucetola R Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia Arch Gen Psychiatry 59 2002 337 345
51. Yang SH, and McNeely MJ Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone Am J Psychiatry 159 2002 1435
52. Koller EA, and Doraiswamy PM Olanzapine-associated diabetes mellitus Pharmacotherapy 22 2002 841 852
53. Koller EA, Cross JT, Doraiswamy PM, and Schneider BS Risperidone- associated diabetes mellitus: A pharmacovigilance study Pharmacotherapy 23 2003 735 744
54. Lund BC, Perry PJ, Brooks JM, and Arndt S Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: A claims-based approach Arch Gen Psychiatry 58 2001 1172 1176
55. Caro JJ, Ward A, Levinton C, and Robinson K The risk of diabetes during olanzapine use compared with risperidone use: A retrospective database analysis J Clin Psychiatry 63 2002 1135 1139
56. Farwell W, Stump T, and Wang J Do olanzapine and risperidone cause weight gain and diabetes? Poster presented at: 23rd Collegium Internationale Neuro-Psychopharmacologium Congress Montreal, Canada June 23-27, 2002
57. Gianfrancesco FD, Grogg AL, and Mahmoud RA Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: Findings from a large health plan database J Clin Psychiatry 63 2002 920 930
58. [serial online] Koro CE, Fedder DO, and L'Italien GJ Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: Population based nested case-control study BMJ 325 2002 243
59. Sernyak MJ, Leslie DL, and Alarcon RD Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia Am J Psychiatry 159 2002 561 566
60. Wang PS, Glynn RJ, and Ganz DA Clozapine use and risk of diabetes mellitus J Clin Psychopharmacol 22 2002 236 243
61. Buse JB, Cavazzoni P, and Hornbuckle K A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States J Clin Epidemiol 56 2003 164 170
62. Abstract Citrome L, Jaffe A, and Levine J Antipsychotic medication treatment and new prescriptions for insulin and oral hypoglycemics Eur Neuropsychopharmacol 13 Suppl 4 2003 S306
63. Fuller MA, Shermock KM, Secic M, and Grogg AL Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine Pharmacotherapy 23 2003 1037 1043
64. Gianfrancesco F, White R, Wang RH, and Nasrallah HA Antipsychotic-induced type 2 diabetes: Evidence from a large health plan database J Clin Psychopharmacol 23 2003 328 335
65. Grogg A, Markowitz J, and Mahmoud RA Risk of diabetes in medical patients prescribed atypical antipsychotics Abstract presented at: 156th Annual Meeting of the American Psychiatric Association San Francisco, Calif. May 17-22, 2003
66. Citrome L, Jaffe A, and Levine J Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients Psychiatr Sev 55 2004 1006 1013
67. Abstract Lambert BL, Chou CH, and Chang KY Assessing the risk of antipsychotic-induced type II diabetes among schizophrenics: A matched case-control study Eur Neuropsychopharmacol 12 Suppl 3 2002 S307 S308
68. Leslie BC, and Rosenheck R Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications Am J Psychiatry 161 2004 1709 1711
69. Ollendorf DA, Joyce AT, and Rucker M Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia MedGenMed 6 2004 5
70. Sumiyoshi T, Roy A, and Anil AE A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: A survey for clozapine, risperidone, olanzapine, and quetiapine J Clin Psychopharmacol 24 2004 345 348
71. Available at: American Diabetes Association Diabetes Facts and Figures Accessed September 29, 2004
72. Melkersson KI, and Hulting AL Insulin and leptin levels in patients with schizophrenia or related psychoses--a comparison between different antipsychotic agents Psychopharmacology (Berl) 154 2001 205 212
73. Ebenbichler CF, Laimer M, and Eder U Olanzapine induces insulin resistance: Results from a prospective study J Clin Psychiatry 64 2003 1436 1439
74. Simpson GM, Glick ID, and Weiden PJ Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder Am J Psychiatry 161 2004 1837 1847
75. Abstract Simpson G, Weiden P, Pigott TA, and Romano S Ziprasidone vs. olanzapine in schizophrenia: 6-Month continuation study Eur Neuropsychopharmacol 12 2002 S310
76. Melkersson KI, and Dahl ML Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses Psychopharmacology (Berl) 170 2003 157 166
77. Melkersson KI, Hulting AL, and Brismar KE Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses J Clin Psychiatry 61 2000 742 749
78. Montague CT, and O'Rahilly S The perils of portliness: Causes and consequences of visceral adiposity Diabetes 49 2000 883 888
79. Resnick HE, Valsania P, Halter JB, and Lin X Differential effects of BMI on diabetes risk among black and white Americans Diabetes Care 21 1998 1828 1835
80. Lindenmayer JP, Czobor P, and Volavka J Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics Am J Psychiatry 160 2003 290 296
81. Atmaca M, Kuloglu M, Tezcan E, and Ustundag B Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics J Clin Psychiatry 64 2003 598 604
82. Vanelle JM, and Douki S An 8-week double blind, randomized trial comparing amisulpride and olanzapine in schizophrenic patients with depression Poster presented at: 24th Collegium Internationale Neuro-Psychopharmacologium Congress Paris, France June 20-21, 2004
83. L'Italien GJ Pharmacoeconomic impact of antipsychotic-induced metabolic events Am J Manag Care 3 2003 S38 S42
84. Casey DE, L'Italien GJ, and Waldeck R Metabolic syndrome comparison between olanzapine, aripiprazole, and placebo Poster presented at: 156th Annual Meeting of the American Psychiatric Association San Francisco, Calif. May 17-22, 2003